Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...
Le Lézard

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology, Inc. ("Citius Oncology" or the "Company") , the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , today announced that it has entered into a definitive ...